Clinical Trials Logo

Clinical Trial Summary

This study aims to investigate the clinical activity of sunitinib in patients with advanced thymic carcinoma who have failed chemotherapy.


Clinical Trial Description

Sunitinib (Sutent®; Pfizer, New York, NY, USA) is a multitargeted tyrosine-kinase inhibitor (TKI) with activity against the stem cell-factor receptor (KIT) and platelet-derived growth-factor receptor (PDGFR), vascular endothelial growth-factor receptor (VEGFR), glial cell line-derived neurotrophic factor receptor (rearranged during transfection [RET]), colony-stimulating factor-1 receptor (CSF1R), and Fms-like tyrosine kinase-3 receptor (FLT3).

Sunitinib is a potent inhibitor of mutant KIT with additional inhibitory effects on VEGF receptors that potentially might make it more effective than imatinib against TCs. In the current version of NCCN guideline, sunitinib is suggested as one of the potential targeted therapeutics for advanced TCs.

We planned this study to investigate the clinical efficacy and tolerability of sunitinib in patients with advanced or recurrent TCs in Korean population. In addition, we will collect tumor samples and blood samples from patients for the further exploration of predictive biomarkers. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02623127
Study type Interventional
Source Seoul National University Hospital
Contact
Status Completed
Phase Phase 2
Start date October 2015
Completion date October 2018

See also
  Status Clinical Trial Phase
Recruiting NCT06019468 - Neoadjuvant Treatment For Locally Advanced Thymic Cancer Phase 2
Terminated NCT00818090 - Paclitaxel and Cisplatin for Thymic Neoplasm Phase 2
Active, not recruiting NCT03921671 - Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT) Phase 2
Active, not recruiting NCT02364076 - Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma Phase 2
Terminated NCT01100944 - A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies Phase 1/Phase 2
Recruiting NCT03449173 - Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Phase 2
Recruiting NCT03556228 - Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Phase 1
Completed NCT01364727 - A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Phase 2
Suspended NCT03463460 - Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer Phase 2
Completed NCT00010257 - Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma Phase 2
Completed NCT04430842 - Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S Phase 1
Active, not recruiting NCT03583086 - Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors Phase 1/Phase 2
Completed NCT03517488 - A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors Phase 1
Completed NCT00198133 - Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Phase 2
Recruiting NCT03170804 - Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer N/A
Recruiting NCT05667948 - Molecular Analysis and Treatment Options of Thymic Malignancies
Terminated NCT01011439 - Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Phase 2
Terminated NCT01143545 - Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas Phase 1
Completed NCT02307500 - Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy Phase 2
Active, not recruiting NCT01025089 - Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma Phase 2